Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants
This study has been completed.
Sponsor:
Novartis Vaccines
Information provided by (Responsible Party):
Novartis ( Novartis Vaccines )
ClinicalTrials.gov Identifier:
NCT00937521
First received: June 29, 2009
Last updated: February 22, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.
| Condition | Intervention | Phase |
|---|---|---|
|
Meningococcal Meningitis Meningococcal Infections |
Biological: Meningococcal B vaccine Biological: Control Biological: Meningococcal B vaccine with antipyretic |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
| Official Title: | A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Immune response one month after third vaccination [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Safety and reactogenicity within 3 days after first vaccination [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To compare the immune response of study vaccines at 1 month after third vaccination [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- To compare the immune response of study vaccines and routine vaccines given with or without prophylactic antipyretic treatment [ Time Frame: 3 months and 12 months ] [ Designated as safety issue: No ]
- Safety and reactogenicity of study vaccines within 7 days after second and third vaccination [ Time Frame: 3 months and 12 months ] [ Designated as safety issue: Yes ]
- Safety and reactogenicity of study vaccines co-administered with routine vaccines as compared to control group [ Time Frame: 3 months and 12 months ] [ Designated as safety issue: Yes ]
- Solicited local and systemic reactions [ Time Frame: 3 months and 12 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 1508 |
| Study Start Date: | July 2009 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Vaccine candidate formulation I
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation I
|
|
2
Vaccine candidate formulation II
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation II
|
|
3
Vaccine candidate formulation III
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation III
|
|
4
Vaccine candidate formulation IV
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation IV
|
|
5
Vaccine candidate formulation V
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation V
|
|
6
Vaccine candidate formulation VI
|
Biological: Meningococcal B vaccine
Vaccine candidate formulation VI
|
|
7
Control
|
Biological: Control
Control
|
|
8
Vaccine candidate formulation I with antipyretic
|
Biological: Meningococcal B vaccine with antipyretic
Vaccine candidate formulation I with antipyretic
|
Eligibility| Ages Eligible for Study: | 55 Days to 89 Days |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy 2-month old infants (55-89 days, inclusive), born after full term pregnancy, gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg
- Available for all the visits scheduled in the study and for whom a parent/legal guardian is willing/able to comply with all protocol requirements
Exclusion Criteria:
- Any meningococcal B or C vaccine administration
- Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell), Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), and Pneumococcal antigens;
- Any ascertained or suspected disease caused by N. meningitidis
- Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis
- History of severe allergic reaction after previous vaccinations
- Recent significant acute or chronic infection
- Oral or parenteral antibiotic treatment in the 7 days prior to the scheduled blood draw;
- Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, progressive neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition)
Any impairment/alteration of the immune system resulting from (for example):
- Receipt of any immunosuppressive therapy at any time since birth
- Receipt of immunostimulants at any time since birth
- Use of systemic corticosteroids or chronic use of inhaled high-potency corticosteroids at any time since birth
- Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation
- Participation in another clinical trial
- Family members and household members of research staff
- History of seizure
- Any contraindication to paracetamol
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00937521
Locations
| Argentina | |
| Hospital Privado de Córdoba CMC SA | |
| Naciones Unidas 346, Cordoba, Argentina, X5016KHE | |
| Chile | |
| Universidad de Chile, Av Independencia 1027 | |
| Comuna de Independencia, Santiago, Chile | |
| Consultorio Manuel Bustos | |
| Lo Cruzat 486, Quilicura, Santiago, Chile | |
| Czech Republic | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| O. Kubina 17, Boskovice, Czech Republic, 680 01 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Neklez 3, Brno, Czech Republic, 628 00 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Pernštýnská 127/l, Chlumec nad Cidlinou, Czech Republic, 503 51 | |
| Zdravotní středisko | |
| Vaclavska 4186, Chomutov, Czech Republic, 430 03 | |
| Nemocnice Decin, Detske oddělení | |
| U nemocnice 1, Děčín, Czech Republic, 405 01 | |
| Fakulta vojenskeho zdravotnictvi UO | |
| Trebešská 1575, Hradec Králové, Czech Republic, 50001 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Masarykova 389, Humpolec, Czech Republic, 396 01 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Ruských legii 352, Jindřichův Hradec, Czech Republic, 377 01 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Hrnčířská 1401, Lipník nad Bečvou, Czech Republic, 751 31 | |
| Oblastni nemocnice Nachod, Destske oddělení | |
| Purkyňova 446, Náchod, Czech Republic, 547 01 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| U lékárny 306, Odolena Voda, Czech Republic, 250 70 | |
| Prakticky lekar pro deti a dorost | |
| Dvouletky 54, Ostrava, Czech Republic, 700 30 | |
| KHS Ostrava, Protiepidemické oddělení | |
| Na Bělidle 7, Ostrava, Czech Republic, 702 00 | |
| Nemocnice Pardubice, Destske odděleni | |
| Kyjevská 44, Pardubice, Czech Republic, 532 03 | |
| Fakultni nemocnice Bory | |
| E. Beneše 13, Plzeň, Czech Republic, 305 99 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Chrudimska 2a, Praha 3, Czech Republic, 130 00 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Kladenská 53, Praha 6, Czech Republic, 160 00 | |
| Samostatna ordinace praktickeho lekare pro deti a dorost | |
| Velka Michalska 22, Znojmo, Czech Republic, 669 00 | |
| Hungary | |
| Házi Gyermekorvosi szolgálat | |
| Honvéd u.2., Bordány, Hungary, 6795 | |
| Medszolg 2000 Bt, 6723, Szeged, Dandár u.4 | |
| Ányos u.4., Budapest, Hungary, 1031 | |
| Erzsébet Kórház Gyermekosztály | |
| Hodmezovasarhely, dr. Imre József u.2., Hungary | |
| Baby Box Bt,, 6724, Szeged, Kossuth Lajos sgt.109 | |
| Szeged, Kossuth Lajos sgt.109, Hungary | |
| Dr. Bán Mariann és Társa Bt. | |
| Kando Kalman u.1, Miskolc, Hungary, 3534 | |
| Futurnest Kft | |
| Selyemrét u.1., Miskolc, Hungary, 3527 | |
| Ped-Med Kft. , 3434 Mályi, Fő u.12. | |
| Fő u.12., Mályi, Hungary, 3434 | |
| S.K. Sipka és Kovács Eü. Bt. | |
| Csongrádi sgt. 63., Szeged, Hungary, 6723 | |
| Oszila Kft. 6723, Szeged, Debreceni u.10-14. | |
| Debreceni u.10-14., Szeged, Hungary, 6723 | |
| Győriné dr. Bari Eszter egyéni vállalkozó | |
| Csongrad, Szentháromság tér 10, Hungary | |
| Vas Megyei Markusovszky Kórház, Gyermekosztály | |
| Markusovszky u. 1-3, Szombathely, Hungary, 9700 | |
| Italy | |
| Dipartimento di Neonatologia e Terapia Intensiva Neonatale, "Ospedale dei Bambini", Presidio Ospedaliero dell'Azienda Ospedaliera Spedali Civili di Brescia | |
| P.le Spedali di Brescia,1, Brescia, Italy, 25125 | |
| Dipartimento di Pediatria dell'Università degli Studi di Firenze | |
| Viale Pieraccini n. 24, Firenze, Italy, 50139 | |
| Università degli Studi di Messina, Pad. NI - A.O.U. Policlinico G.Martino | |
| Via Consolare Valeria, 1, Messina, Italy, 98125 | |
| Fondazione IRCCS dell'Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena di Milano | |
| Via Commenda, 9, Milano, Italy, 20122 | |
| Pediatria dell'Ospedale Sacco di Milano | |
| Via G.B.Grossi 74, Milano, Italy, 20157 | |
| Dipartimento di Pediatria Azienda Ospedaliera di Padova | |
| Via Giustiniani, 3, Padova, Italy, 35128 | |
Sponsors and Collaborators
Novartis Vaccines
More Information
No publications provided
| Responsible Party: | Novartis ( Novartis Vaccines ) |
| ClinicalTrials.gov Identifier: | NCT00937521 History of Changes |
| Other Study ID Numbers: | V72P16, 2009-010106-11 |
| Study First Received: | June 29, 2009 |
| Last Updated: | February 22, 2012 |
| Health Authority: | Italy: AIFA |
Keywords provided by Novartis:
|
Immunogenicity Meningitis Antibody Infants |
Additional relevant MeSH terms:
|
Meningitis Meningitis, Meningococcal Meningococcal Infections Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Meningitis, Bacterial |
Central Nervous System Bacterial Infections Bacterial Infections Neisseriaceae Infections Gram-Negative Bacterial Infections Antipyretics Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013